Marina V. Lebedeva

Marina V. Lebedeva


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Russian Journal of Occupational Health and Industrial Ecology
Verified
Journal Article
Closed access
PDF file
LSL. A. Strizhakov
L. A. Strizhakov
SBS. A. Babanov
S. A. Babanov
DBD. S. Budash
D. S. Budash
MLMarina V. Lebedeva
Marina V. Lebedeva
ABA. G. Baikova
A. G. Baikova
SMSergey V. Moiseev
Sergey V. Moiseev
Иммунологические особенности и прогнозирование при современных формах профессиональных заболеваний легких

Verified
Journal Article
Open access
PDF file
NCNatalia V. Chebotareva
Natalia V. Chebotareva
AVAnatoliy Vinogradov
Anatoliy Vinogradov
ABAlexander Brzhozovskiy
Alexander Brzhozovskiy
DKDaria N. Kashirina
Daria N. Kashirina
MIMaria Indeykina
Maria Indeykina
Alexey S. KononikhinAlexey S. Kononikhin
Alexey S. Kononikhin
Primary focal segmental glomerulosclerosis (FSGS), along with minimal change disease (MCD), are diseases with primary podocyte damage that are clinically manifested by the nephrotic syndrome. The pathogenesis of these podocytopathies is still unknown, and therefore, the search for biomarkers of these diseases is ongoing. Our aim was to determine of the proteomic profile of urine from patients with FSGS and MCD. Patients with a confirmed diagnosis of FSGS (n = 30) and MCD (n = 9) were recruited for the study. For a comprehensive assessment of the severity of FSGS a special index was introduced, which was calculated as follows: the first score was assigned depending on the level of eGFR, the second score—depending on the proteinuria level, the third score—resistance to steroid therapy. Patients with the sum of these scores of less than 3 were included in group 1, with 3 or more—in group 2. The urinary proteome was analyzed using liquid chromatography/mass spectrometry. The proteome profiles of patients with severe progressive FSGS from group 2, mild FSGS from group 1 and MCD were compared. Results of the label free analysis were validated using targeted LC-MS based on multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS) available for 47 of the 76 proteins identified as differentiating between at least one pair of groups. Quantitative MRM SIS validation measurements for these 47 proteins revealed 22 proteins with significant differences between at least one of the two group pairs and 14 proteins were validated for both comparisons. In addition, all of the 22 proteins validated by MRM SIS analysis showed the same direction of change as at the discovery stage with label-free LC-MS analysis, i.e., up or down regulation in MCD and FSGS1 against FSGS2. Patients from the FSGS group 2 showed a significantly different profile from both FSGS group 1 and MCD. Among the 47 significantly differentiating proteins, the most significant were apolipoprotein A-IV, hemopexin, vitronectin, gelsolin, components of the complement system (C4b, factors B and I), retinol- and vitamin D-binding proteins. Patients with mild form of FSGS and MCD showed lower levels of Cystatin C, gelsolin and complement factor I.

30 June 2021 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
NCNatalia V. Chebotareva
Natalia V. Chebotareva
SBSvetlana Berns
Svetlana Berns
ABAngelina Berns
Angelina Berns
TATatyana Androsova
Tatyana Androsova
MLMarina V. Lebedeva
Marina V. Lebedeva
SMSergey V. Moiseev
Sergey V. Moiseev
The development of acute kidney injury (AKI) in patients with coronavirus disease 2019 (COVID-19) is associated with a high risk of death. Published data demonstrate the possibility of severe kidney injury in patients suffering from COVID-19. However, these data are still controversial. A total of 1,280 patients with a proven diagnosis of COVID-19 were included in our study. COVID-19 was confirmed in all patients using reverse transcriptase polymerase chain reaction test of a nasopharyngeal swab, and based on the typical computed tomography findings. Demographic data, underlying comorbidities, and laboratory blood tests were assessed. We assessed the incidence of AKI and its associated mortality defined by survival status at discharge. Proteinuria was identified with 648 patients (50.6%) with COVID-19. AKI was identified in 371 patients (29.0%). Ten of these patients (2.7%) required dialysis. The risk factors for AKI included age of > 65 years, augmentation of C-reactive protein, ferritin and an increase in values of activated partial thromboplastin time. Overall, 162 of the 1,280 hospitalized patients (12.7%) and 111 of the 371 patients (29.9%) with AKI did not survive. The hazard ratio (HR) for mortality was 3.96 (95% confidence interval, 2.83-5.54) for patients with AKI vs. no AKI. AKI was a relatively common finding among patients with COVID-19. The risk factors for AKI in COVID-19 included old age, the inflammatory response, the severity of lung involvement, and disseminated intravascular coagulation. These same factors, in addition to arterial hypertension, were found to increase the risk of mortality.

9 July 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LMLudmila Yu. Milovanova
Ludmila Yu. Milovanova
L(Lidia V. Lysenko (Kozlovskaya)
Lidia V. Lysenko (Kozlovskaya)
SMSvetlana Yu. Milovanova
Svetlana Yu. Milovanova
MTMarina V. Taranova
Marina V. Taranova
VKVasiliy V. Kozlov
Vasiliy V. Kozlov
NCNatalia V. Chebotareva
Natalia V. Chebotareva
Cardiovascular calcification (CVC) makes a significant contribution to the manifestation of cardiovascular complications in patients with chronic kidney disease. Early CVC markers are currently being actively studied to optimize cardio-renoprotective strategies. We performed a prospective comparative analysis of the following factors: FGF-23, a-Klotho, sclecrostin, phosphate, parathyroid hormone, the estimated glomerular filtration rate (eGFR), central systolic pressure as an independent determinant of CVC. Materials and methods. The study included 131 patients with chronic kidney disease 25D st. Serum levels of FGF-23, Klotho, and sclerostin were evaluated using the ELISA method. Vascular augmentation (stiffness) indices, central arterial pressure (using the SphygmoCor device), calcification of heart valves and the degree of aortic calcification (aortic radiography) were also investigated. The observation period was 2 years. Results. According to the Spearman correlation analysis, the percent of calcification increase and the change in Klotho level are most related. According to ROC analysis, a decrease in serum levels of Klotho by 50 units or more is a significant predictor of an increase in aortic calcification of 50% or more with a sensitivity of 86% and a specificity of 77%. Using logistic regression analysis, it was found that a serum Klotho level 632 pg/L predicts an eGFR below a median level of 48 ml/min/1.73 m2 with a sensitivity of 85.5% and a specificity of 78.5%. Wherein OR 17.477 (CI 95% 8.04637.962; p0.001). Conclusion. The factor most associated with CVC is Klotho. Decreased serum level of Klotho is a predictor of aortic calcification. In addition, the initial serum level of Klotho is a predictor of eGFR after 2 years.

13 September 2016 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
LML. Y. Milovanova
L. Y. Milovanova
NMN. A. Mukhin
N. A. Mukhin
LKL. V. Kozlovskaya
L. V. Kozlovskaya
YMY. S. Milovanov
Y. S. Milovanov
GKG. G. Kiyakbaev
G. G. Kiyakbaev
MTM. V. Taranova
M. V. Taranova
Цель исследования: определить значение изменения сывороточного уровня белка Klotho (s-Klotho) у пациентов с хронической болезнью почек (ХБП) 1–5D стадий. Методы. Обследованы 130 больных ХБП 1–5D стадий (67 мужчин и 63 женщины; средний возраст 41±6,7 года). Причинами ХБП у обследованных больных были хронический гломерулонефрит ― у 30, тубулоинтерстициальный нефрит (лекарственной, подагрической этиологии) ― у 23, поликистоз почек ― у 22, гипертензивный нефросклероз ― у 28, сахарный диабет 2-го типа ― у 27. У всех больных исходно и через 1 год наблюдения исследованы сывороточные уровни паратиреоидного гормона (ПТГ), кальция, фосфора, белка s-Klotho (методика ELISA). Всем пациентам измеряли уровень артериального давления (АД), в том числе центрального (аортального), скорость пульсовой волны с помощью аппарата SphygmоCor (Австралия); выполняли эхокардиографию, рентгенографию брюшной аорты в боковой проекции. Результаты. При сравнении уровня s-Klotho у больных с разными стадиями ХБП оказалось, что по мере снижения скорости клубочковой фильтрации (СКФ) его изменение в сыворотке начинается уже с 3А стадии ХБП и опережает повышение уровня фосфора и ПТГ, которые отмечены с 4–5-й стадии ХБП. Согласно ROC-анализу, значение s-Klotho ниже 387 пг/мл с чувствительностью 80% и специфичностью 75% свидетельствовало об увеличении риска кальцификации aбдоминальной аорты. Кроме того, выявлена cтатистически значимая отрицательная взаимосвязь низкого уровня s-Klotho c ремоделированием сердца (развитие гипертрофии левого желудочка и кардиомиопатии). При сравнении пациентов с артериальной гипертензией, которые получали антигипертензивную монотерапию, наиболее высокий уровень белка s-Klotho отмечен у пациентов, у которых целевой уровень АД был достигнут преимущественно с помощью блокаторов рецепторов к ангиотензину II, по сравнению с теми, кто использовал другие группы препаратов (р<0,01) или не достиг целевого уровня АД (p=0,008). Заключение. Изменение сывороточного уровня Klotho (снижение) по мере прогрессирования ХБП ассоциировано с увеличением степени ремоделирования сердца и кальцификации сердца и сосудов и может рассматриваться в качестве раннего самостоятельного маркера поражения сердечно-сосудистой системы при ХБП. Полученные нами предварительные данные о влиянии коррекции АД на уровень s-Klotho свидетельствуют о возможности медикаментозного поддержания сывороточного уровня s-Klotho и требуют дальнейших исследований.

2 September 2024 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
LMLudmila Yu. Milovanova
Ludmila Yu. Milovanova
KNKirill S. Nezhdanov
Kirill S. Nezhdanov
SMSvetlana Yu. Milovanova
Svetlana Yu. Milovanova
MLMarina V. Lebedeva
Marina V. Lebedeva
VBVladimir D. Beketov
Vladimir D. Beketov
SMSergey V. Moiseev
Sergey V. Moiseev
Background α-Klotho deficiency may increase cardiovascular risks and worsen survival. We evaluated the association of α-Klotho with cardiovascular and all-cause mortality in pre-dialysis chronic kidney disease (CKD) patients. Methods In this prospective study, 75 non-diabetic CKD stage 3b–4 patients were followed-up for a median of 8 years. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Human soluble α-Klotho ELISA Assay (IBL-Takara 27,998-96Well), Human Fibroblast Growth Factor-23 ELISA Assay (intact FGF23, Merck Millipore MILLENZ FGF23-32 K), and Human Sclerostin ELISA kits (Biomedica, Vienna, BI-20492) were used to measure serum α-Klotho, FGF23 and sclerostin levels in the certified laboratory at the Sechenov University according to the manufacturers’ protocols. All patients underwent echocardiography to evaluate left ventricular mass index (LVMI), left ventricular ejection fraction by Simpson method, and cardiac (valve) calcification score by a semi-quantitative point scale. Lateral abdominal radiography by Kauppila method was used to estimate calcification of the abdominal aorta. Cox multivariate regression and receiver-operating characteristic curve (ROC)-analysis were used to evaluate risk factors for death and their cut-off values. Results Primary and secondary endpoints were reached in 15 (20%) and 9 (12%) patients, respectively. Median α-Klotho levels in deceased and surviving patients were 344 and 484 pg/ml, respectively (p = 0.002). In a multivariate Cox regression model, baseline α-Klotho levels (HR 0.99, 95% CI 0.98–1.00, p = 0.023), aortic calcification (HR 1.18, 95% CI 1.02–1.36, p = 0.029) and left ventricular mass index (LVMI) (HR 1.04, 95% CI 1.00–1.08, p = 0.033) were associated with the primary endpoint, whereas α-Klotho (HR 0.99, 95% CI 0.98–1.00, p = 0.029), aortic calcification (HR 1.23, 95% CI 1.07–1.42, p = 0.003) and LVMI (HR 1.04, 95% CI 1.00–1.08, p = 0.021) were associated with the secondary endpoint. α-Klotho levels had the highest area under the curve (AUC) by ROC analysis, that is, 0.766 (95% CI 0.70–0.82) for the primary endpoint and 0.842 (95% CI 0.79–0.90) for the secondary endpoint with cut-off values of 412 pg/ml (HR 3.06, 95% CI 1.36–6.89, p = 0.007) and 368 pg/ml (HR 4.84, 95% CI 1.59–14.73, p = 0.005), respectively. Conclusion In pre-dialysis CKD patients, α-Klotho levels are associated with all-cause and cardiovascular mortality and may be considered an early prognostic marker. Graphical abstract